Search Results

You are looking at 201 - 210 of 534 items for :

  • "pathology" x
  • Refine by Access: All x
Clear All
Full access

Oncology Research Program (ORP) and Bristol-Myers Squibb (BMS) are collaborating on the NCCN/BMS Thoracic Pathology Protocol Development Team. This team will be responsible for a study designed to: understand how different assays measure PD-L1 protein

Full access

Jaffer A. Ajani, Thomas A. D’Amico, David J. Bentrem, Joseph Chao, David Cooke, Carlos Corvera, Prajnan Das, Peter C. Enzinger, Thomas Enzler, Paul Fanta, Farhood Farjah, Hans Gerdes, Michael K. Gibson, Steven Hochwald, Wayne L. Hofstetter, David H. Ilson, Rajesh N. Keswani, Sunnie Kim, Lawrence R. Kleinberg, Samuel J. Klempner, Jill Lacy, Quan P. Ly, Kristina A. Matkowskyj, Michael McNamara, Mary F. Mulcahy, Darryl Outlaw, Haeseong Park, Kyle A. Perry, Jose Pimiento, George A. Poultsides, Scott Reznik, Robert E. Roses, Vivian E. Strong, Stacey Su, Hanlin L. Wang, Georgia Wiesner, Christopher G. Willett, Danny Yakoub, Harry Yoon, Nicole McMillian, and Lenora A. Pluchino

pathology assessments to establish cTNM and ypTNM stages has never been validated and may not be appropriate. Therefore, new cTNM and ypTNM stage groupings and prognostic information were added to the eighth edition to overcome these issues. New clinical

Full access

Katy K. Tsai, Neharika Khurana, Timothy McCalmont, Adil Daud, Boris Bastian, and Iwei Yeh

resected in late April 2015, with pathology indicating poorly differentiated clear cell carcinoma ( Figure 1 ). The tumor was 9.8 cm in greatest diameter and was excised with a positive margin. Focal perineural invasion and vaguely squamoid areas were also

Full access

Robert W. Carlson and on behalf of the NCCN Breast Cancer Panel

about the reliability of biomarker testing in breast cancer. ASCO, the College of American Pathology, and NCCN issued technology assessments on methods to assure high-quality performance and interpretation of ER, PR, and HER2 testing. 3 - 6

Full access

Karen L. Rech and Rong He

conditions. The diagnosis requires multidisciplinary integration of the entire picture from the clinical, radiology, laboratory, and pathology perspectives. Clinical Presentation The presenting signs and symptoms of histiocytic neoplasms are diverse, and

Full access

George Handzo, Jill M. Bowden, and Stephen King

publication of the third edition of the NCP guidelines. The panel chose “distress” as the focus of the 1997 NCCN Guidelines because that term did not represent or infer any kind of pathology. Efforts were made to describe distress as a normally expected

Full access

Michael Cecchini, Jeffrey Sklar, and Jill Lacy

neoadjuvant FOLFIRINOX followed by pancreaticoduodenectomy with negative margins and 6 cycles of adjuvant FOLFIRINOX. Surgical pathology revealed ypT3N1Mx (stage IIB) adenocarcinoma. Eight months after completion of adjuvant therapy, PET imaging revealed

Full access

Rajinder S. Grover, Kemp Kernstine, and Amrita Krishnan

final pathology. Figure 1 CT of the face, neck, and torso, and PET/CT showing FDG uptake. CT of the chest with contrast (A) reveals a large mass surrounding the distal esophagus measuring 6.0 x 3.7 cm and extending to the gastroesophageal

Full access

Michael A. Cilento, Nicola K. Poplawski, Sellvakumaram Paramasivam, David M. Thomas, and Ganessan Kichenadasse

tumor from the diaphragm and Gerota fascia. There was no evidence of disease on postoperative imaging. Surgical pathology showed a high-grade serous carcinoma of endometrial origin with the bulk of the tumor arising from the lower fundus, lower uterine

Full access

Mariam Naveed, Meredith Clary, Chul Ahn, Nisa Kubiliun, Deepak Agrawal, Byron Cryer, Caitlin Murphy, and Amit G. Singal

, gastrointestinal symptoms), laboratory data (eg, iron deficiency anemia), radiologic data (eg, bowel thickening on imaging), and prior pathology and colonoscopy data (eg, history of adenomas). Family history of colon cancer denoting high-risk screening was defined